Angelman syndrome

Dra. Pepi Rivera, Director of the Pediatric Medicine Service at Parc Taulí and Coordinator of the Rare Diseases Unit

Parc Taulí participates in an international trial to improve the symptoms of patients with Angelman syndrome

The Parc Taulí Paediatrics Service has been participating, since last August, in an international clinical trial that aims to reverse the expression of the genetic defect of children with Angelman syndrome, which could lead to an important improvement in the symptomatology of patients diagnosed with this minority disease. This is a project promoted by the pharmaceutical company F. Hoffman-La Roche, which will have about 60 patients from all over the world, including 3 patients from Parc Taulí, with the intention of incorporating ne 3 more over the next few months. read more

Privacy preferences

When you visit our website, your browser may store information about specific services, usually in the form of cookies. Here you can change your privacy preferences. Please note that blocking certain types of cookies may affect your experience on our website and the services we offer.

Enable / disable Google Analytics tracking code
Enable / disable Google Fonts
Turn Google Maps on / off
Enable / disable embedded videos
This website uses cookies, mainly from third party services. You can edit your privacy preferences and / or accept the use of cookies.